SG11201401193XA - TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS - Google Patents

TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Info

Publication number
SG11201401193XA
SG11201401193XA SG11201401193XA SG11201401193XA SG11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA
Authority
SG
Singapore
Prior art keywords
obesity
treatment
related disorders
potassium channels
pharmacological targeting
Prior art date
Application number
SG11201401193XA
Other languages
English (en)
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn-Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of SG11201401193XA publication Critical patent/SG11201401193XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201401193XA 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS SG11201401193XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
SG11201401193XA true SG11201401193XA (en) 2014-05-29

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401193XA SG11201401193XA (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Country Status (16)

Country Link
US (2) US20150072940A1 (zh)
EP (1) EP2763702A4 (zh)
JP (1) JP2014531469A (zh)
KR (1) KR20140108518A (zh)
CN (1) CN103987408A (zh)
AU (1) AU2012318736A1 (zh)
BR (1) BR112014008065A2 (zh)
CA (1) CA2850357A1 (zh)
HK (1) HK1201048A1 (zh)
IL (1) IL231873A0 (zh)
IN (1) IN2014CN03333A (zh)
MX (1) MX2014004029A (zh)
RU (1) RU2014117558A (zh)
SG (1) SG11201401193XA (zh)
TW (1) TW201321403A (zh)
WO (1) WO2013052507A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080523B2 (en) * 2004-10-07 2011-12-20 The Regents Of The University Of California Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
RU2637085C2 (ru) * 2011-06-06 2017-11-29 КИНЕТА УАН, ЭлЭлСи Фармацевтические композиции на основе shk и способы их получения и использования
IN2014CN03333A (zh) 2011-10-03 2015-07-03 Univ California
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
TWI698438B (zh) 2015-03-13 2020-07-11 德商4Sc製藥公司 Kv1.3抑制劑及其醫學應用
TWI701249B (zh) 2015-03-13 2020-08-11 德商4Sc製藥公司 Kv1.3抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
WO1999013895A1 (en) * 1997-09-17 1999-03-25 University Of Florida Polypeptide compositions that inhibit potassium channel activity and uses therefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US8080523B2 (en) 2004-10-07 2011-12-20 The Regents Of The University Of California Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2619480A1 (en) * 2005-08-17 2007-02-22 Solvay Pharmaceuticals Gmbh Method of using potassium channel inhibiting compounds
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
IN2014CN03333A (zh) 2011-10-03 2015-07-03 Univ California

Also Published As

Publication number Publication date
WO2013052507A1 (en) 2013-04-11
CA2850357A1 (en) 2013-04-11
EP2763702A1 (en) 2014-08-13
US9878006B2 (en) 2018-01-30
RU2014117558A (ru) 2015-11-10
EP2763702A4 (en) 2015-04-15
US20150072940A1 (en) 2015-03-12
BR112014008065A2 (pt) 2019-09-24
TW201321403A (zh) 2013-06-01
JP2014531469A (ja) 2014-11-27
AU2012318736A1 (en) 2014-05-22
KR20140108518A (ko) 2014-09-11
MX2014004029A (es) 2014-08-01
US20170095530A1 (en) 2017-04-06
HK1201048A1 (zh) 2015-08-21
IN2014CN03333A (zh) 2015-07-03
IL231873A0 (en) 2014-05-28
CN103987408A (zh) 2014-08-13

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
EP2670478A4 (en) DEVICES, SYSTEMS AND METHODS FOR THE TARGETED TREATMENT OF MOVEMENT DISORDERS
HK1201048A1 (zh) 通過藥理學靶向 鉀通道治療肥胖和肥胖相關病症
EP2575816A4 (en) COMBINATION THERAPY FOR HAIR DRESSES
PL2704704T3 (pl) Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
EP2663304A4 (en) COMBINATION THERAPY
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
ZA201401952B (en) Immunocytokine combination therapy
EP2726095A4 (en) COMBINATION THERAPY
EP2890370A4 (en) AGENTS USEFUL FOR THE TREATMENT OF OBESITY, DIABETES AND RELATED DISORDERS
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
EP2720708A4 (en) AIMING AT THE NEUROMUSCULAR END PLATE FOR TREATMENT PURPOSES
IL225896A0 (en) Treatment of mecp-2 related disorders
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EP2675275A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
EP2701744A4 (en) COMBINATION THERAPY
ZA201308176B (en) Therapeutic treatment
IL214123A0 (en) Massage appatus fo rthe shower
EP2726505A4 (en) THERAPEUTIC TARGETING OF FICOLIN-3
GB0912587D0 (en) Therapeutic uses for plants of the capsicum genus
GB201118065D0 (en) Treatment of movement disorders
AU2012900788A0 (en) Combination treatment for rheumatic disorders
AU335490S (en) Physiotherapy band
AU335277S (en) Physiotherapy band
GB201101183D0 (en) Treatment of neurodegenerative disorders